Focus Partners Wealth
RPRX icon

Focus Partners Wealth’s Royalty Pharma RPRX Stock Holding History

Focus Partners Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.41M Sell
96,526
-19,724
-17% -$1.03M 0.01% 922
2026
Q1 		$5.58M Buy
116,250
+15,582
+15% +$682K 0.01% 897
2025
Q4 		$3.89M Buy
+100,668
New +$3.84M ﹤0.01% 1045
2025
Q3 		– Sell
-5,792
Closed -$209K – 2293
2025
Q2 		$209K Sell
5,792
-2,681
-32% -$88.8K ﹤0.01% 1854
2025
Q1 		$264K Buy
+8,473
New +$269K ﹤0.01% 1632

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Focus Partners Wealth's RPRX Position: Q2 2026 in Review

Focus Partners Wealth reduced its Royalty Pharma (RPRX) stake by 17% in Q2 2026, selling an estimated $1.03M and leaving 96,526 shares worth $5.41M. The position accounts for 0.01% of the portfolio, ranked #922.

Focus Partners Wealth first reported a position in RPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.58M in Q1 2026. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Focus Partners Wealth held 96,526 shares of Royalty Pharma worth $5.41M as of Q2 2026.
  • Focus Partners Wealth sold 19,724 Royalty Pharma shares in Q2 2026, an estimated $1.03M.
  • Royalty Pharma made up 0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #922 holding.
  • Focus Partners Wealth first reported a position in Royalty Pharma in Q1 2025 and has held it in 5 quarters since.
  • Focus Partners Wealth's Royalty Pharma position peaked at $5.58M in Q1 2026.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.